Tularemia is a zoonotic disease caused by the bacterium *Francisella tularensis*. In the United States, approximately 100--300 cases of tularemia are reported to the Centers for Disease Control and Prevention (CDC) annually, and most reported cases occurred in Missouri, Kansas, Arkansas, and Oklahoma over the last decade \[[@CIT0001]\]. With a low infectious dose 50 of 10--25 organisms, *F tularensis* is a very infectious pathogen \[[@CIT0002]\], which raises fears of its potential use as biological weapon \[[@CIT0003]\]. Two subspecies of *F tularensis* cause tularemia in the United States: *F tularensis* subspecies *tularensis* (type A) and *F tularensis* subspecies *holarctica* (type B). Type A strains are more virulent than type B strains, and recent molecular studies have shown that genotype A1b may be significantly more virulent than A1a, A2, or type B strains \[[@CIT0004]\].

Our current knowledge regarding treatment of tularemia is derived from case reports or case series. Treatment options include streptomycin, gentamicin, tetracyclines, and fluoroquinolones \[[@CIT0001], [@CIT0002]\]. Streptomycin has been considered the drug of choice for tularemia since Foshay and Pasternack \[[@CIT0005]\] reported efficacy in 7 patients in 1946. However, streptomycin is difficult to obtain, and due to a shortage at the time, Enderlin et al \[[@CIT0006]\] gathered data about the efficacy of alternative agents for the treatment of tularemia in 1994. In that review, the cure rate for tetracycline was 88% (44 of 50) and the relapse rate was 12% (6 of 50). Three of the 6 patients who relapsed after treatment with tetracycline received less than 7 days of therapy, which, in addition to experiments in humans confirming a relationship between relapse and bacteriostatic action of tetracycline \[[@CIT0007]\], led to recommendations by the CDC to prescribe tetracyclines for at least 14 days \[[@CIT0001]\]. Likewise, the World Health Organization (WHO) recommends prescribing doxycycline for at least 15 days \[[@CIT0002]\]. In a recent review of cases in Missouri, 13 patients were treated for at least 14 days with doxycycline alone or in combination with inappropriate antibiotics, and 2 (15%) of those patients had treatment failures \[[@CIT0008]\]. We performed a retrospective analysis of the treatment of tularemia, based on our good experience with tetracyclines \[[@CIT0009]\].

METHODS {#s1}
=======

We conducted a retrospective review of patients diagnosed with tularemia at the University of Missouri between May 1988 and June 2015. The Institutional Review Board of the University of Missouri approved this study. Patients with tularemia were identified through review of discharge diagnosis (*International Classification of Diseases, Ninth Revision* codes), the infection control department database (which included serology-based and culture-based diagnoses), and the microbiology laboratory database. Diagnosis of tularemia was based on WHO guidelines \[[@CIT0002]\]. Patients with the diagnosis of presumptive tularemia (suggestive clinical symptoms and a clinical sample positive for tularemia by antigen or deoxyribonucleic acid detection or a single positive serology) and confirmed tularemia (culture-positive or paired serum specimens with a 4-fold difference in titer) who were treated with tetracyclines (tetracycline or doxycycline) were identified and included in the study. Determination of subspecies by culture or molecular testing was not done or was not available. Exclusion criteria included use of a non-tetracycline antibiotic active against tularemia, concomitant infection that could confound the determination of cure or relapse, and age below 8 years. Relevant clinical data included age, gender, type of tularemia (ulceroglandular, glandular, typhoidal, oculoglandular, oropharyngeal, pneumonic), month and/or year of presentation, means of diagnosis, need for admission to intensive care unit, prior antibiotic therapy, delay before initiation of tetracycline therapy, duration of tetracycline therapy, necessity for aspiration or incision and drainage, and outcome.

Cure was defined as resolution of all symptoms (eg, fever, lymphadenopathy, ulcer, conjunctivitis, respiratory symptoms) after completion of therapy. If aspiration or incision and drainage were required after initiation of tetracycline therapy, treatment was considered successful if patients were continued on tetracycline therapy after the procedure and met the definition of cure after treatment. Relapse was defined as recurrence of symptoms after resolution and completion of the initial course of tetracyclines. Follow-up information on cure and relapse was obtained from the chart or a telephone contact with patient or guardian; the timing of this follow up ranged from 1 year after the episode to several years later.

RESULTS {#s2}
=======

A total of 48 patients with diagnosis of tularemia were identified in the study period. After excluding (1) 20 patients who received non-tetracycline antibiotics active against tularemia (most of them treated with gentamicin alone, ciprofloxacin alone, gentamicin/ciprofloxacin combination, or tetracycline combined with either gentamicin or ciprofloxacin, and 1 patient treated sequentially with chloramphenicol, streptomycin, and gentamicin), (2) 1 patient with a concomitant infection (*Staphylococcus aureus* bacteremia), and (3) 10 patients younger than 8 years of age, 17 patients were included in the study ([Table 1](#T1){ref-type="table"}). Tularemia was confirmed in 3 cases and 14 cases were presumptive. The median age was 42 years. The majority of the patients were male (52.9%). Most of the patients were diagnosed in April--October (88%). Seven patients (41%) had the glandular type, 6 patients (35%) had the ulceroglandular type, 3 patients (17.6%) had the typhoidal type, and 1 patient (6%) had the oculoglandular type. Several patients were hospitalized, but none of the patients required admission to the intensive care unit. Most of these patients (11 of 17, 65%) had received ineffective antibiotic therapy before presentation, commonly a β-lactam. An average of 27 days had elapsed from the onset of symptoms to the first dose of a tetracycline. Median duration of oral tetracycline therapy was 21 days (range, 10--42 days). Except for 1 patient who was treated with 1 gram of tetracycline every 6 hours in 1988, the other 16 patients received 100 mg of doxycycline twice a day. Nine patients underwent either needle aspiration or incision and drainage of abscessed lymph nodes before initiation of tetracycline or doxycycline therapy. Three of those patients required a repeat aspiration or surgical drainage while on doxycycline therapy: the first patient required incision and drainage on day 14 of doxycycline and received 14 additional days of doxycycline after the procedure; the second patient required aspiration on day 14 day of doxycycline and received 4 additional weeks of doxycycline after the procedure; the third patient required needle aspiration on day 7 of doxycycline, underwent incision and drainage on day 14 of doxycycline, and received 1 additional week of doxycycline after the procedure. All 17 patients were cured with no relapses.

###### 

Characteristics of Patients With Tularemia Treated With Tetracyclines

  Patient   Age   Sex   Year/Month of Diagnosis   Type of Tularemia   Diagnosis         Prior Antibiotic Therapy                       Delay Before Tetracycline Therapy   Tetracycline Used/Duration of Therapy   Surgical Procedure^a^      Outcome
  --------- ----- ----- ------------------------- ------------------- ----------------- ---------------------------------------------- ----------------------------------- --------------------------------------- -------------------------- -----------------
  1         62    F     1988/November             Ulceroglandular     Single serology   Cephalexin, ceftriaxone                        28 days                             Tetracycline/10 days                    Aspiration                 Cure/no relapse
  2         8     M     1991/June                 Ulceroglandular     Single serology   Cephalexin, erythromycin                       14 days                             Doxycycline/21 days                     Aspiration                 Cure/no relapse
  3         66    F     1994/August               Glandular           Single serology   None                                           Unknown                             Doxycycline/28 days                     Incision and drainage^b^   Cure/no relapse
  4         76    F     1995/August               Ulceroglandular     Single serology   Clarithromycin, amoxicillin/ clavulanic acid   28 days                             Doxycycline/28 days                     Incision and drainage      Cure/no relapse
  5         42    M     1995/August               Glandular           Single serology   Unknown                                        21 days                             Doxycycline/21 days                     None                       Cure/no relapse
  6         37    M     1996/May                  Ulceroglandular     Culture           Cloxacillin                                    10 days                             Doxycycline/42 days                     Aspiration^c^              Cure/no relapse
  7         36    F     2000/May                  Glandular           Culture           Cephalexin, clindamycin                        21 days                             Doxycycline/21 days                     Incision and drainage^d^   Cure/no relapse
  8         9     F     2001/May                  Glandular           Single serology   Amoxicillin, cephalexin                        28 days                             Doxycycline/21 days                     Aspiration                 Cure/no relapse
  9         46    M     2002/June                 Typhoidal           Single serology   Amoxicillin/clavulanic acid                    21 days                             Doxycycline/14 days                     None                       Cure/no relapse
  10        77    F     2002/July                 Ulceroglandular     Single serology   None                                           56 days                             Doxycycline/14 days                     None                       Cure/no relapse
  11        91    F     2010/April                Oculoglandular      Culture           Vancomycin, ceftriaxone, metronidazole         7 days                              Doxycycline/10 days                     None                       Cure/no relapse
  12        19    M     2011/October              Glandular           Single serology   None                                           42 days                             Doxycycline/14 days                     Aspiration                 Cure/no relapse
  13        32    M     2012/August               Typhoidal           Single serology   None                                           Unknown                             Doxycycline/21 days                     None                       Cure/no relapse
  14        31    M     2012/August               Typhoidal           Single serology   None                                           Unknown                             Doxycycline/21 days                     None                       Cure/no relapse
  15        44    F     2013/January              Glandular           Single serology   Azithromycin                                   84 days                             Doxycycline/14 days                     None                       Cure/no relapse
  16        72    M     2014/October              Ulceroglandular     Single serology   Cephalexin, ceftriaxone, TMP-SMX               7 days                              Doxycycline/21 days                     Incision and drainage      Cure/no relapse
  17        11    M     2015/August               Glandular           Single serology   Amoxicillin/clavulanic acid, cephalexin        10 days                             Doxycycline/14 days                     None                       Cure/no relapse

Abbreviations: F, female; M, male; SMX, sulfamethoxazole; TMP, trimethoprim.

^a^Initial procedures done before initiation of tetracycline or doxycycline therapy.

^b^Required repeat incision and drainage on day 14 of doxycycline.

^c^Required repeat aspiration on day 14 of doxycycline.

^d^Required aspiration on day 7 of doxycycline and incision and drainage on day 14 of doxycycline.

DISCUSSION {#s3}
==========

Streptomycin and tetracyclines are the antibiotics approved by the US Food and Drug Administration (FDA) for treating tularemia. The CDC \[[@CIT0001]\] and WHO \[[@CIT0002]\] recommend aminoglycosides (streptomycin if available or gentamicin) for severe tularemia and tetracyclines or fluoroquinolones for less severe cases. Aminoglycosides are given parenterally and can be ototoxic and nephrotoxic. Tetracyclines and fluoroquinolones have a better toxicity profile and can be given orally. If tetracyclines are used, both guidelines recommend at least 14--15 days of therapy to reduce the risk of relapse due to their bacteriostatic nature. Fluoroquinolones are not FDA approved for treatment of tularemia, but several studies have shown bactericidal activity in vitro and in animal models \[[@CIT0010], [@CIT0011]\], and good efficacy in humans \[[@CIT0008], [@CIT0012]\], as well as lower therapeutic failure rates when compared with doxycycline \[[@CIT0012], [@CIT0014]\].

In our study, all of the patients were cured, and none relapsed after treatment with tetracycline or doxycycline. Except for 1 patient who received tetracycline in 1988, all patients received doxycycline, which, in general, has replaced tetracycline due to pharmacokinetic reasons \[[@CIT0002]\]. More importantly, 9 patients (53%) underwent aspiration or incision and drainage of abscessed lymph nodes before initiation of therapy, and 3 patients required repeat procedure while on doxycycline. Doxycycline therapy was not changed after the repeat procedures in these 3 patients, but it was extended for an additional 1 to 4 weeks. The median duration of 21 days was longer than the minimum recommended; 7 of the 9 patients (78%) who required any surgical procedure received at least 21 days of therapy.

Our experience with tetracyclines contrasts with the relapse rate of 15% reported by Weber et al \[[@CIT0008]\], 42.8% reported by Pérez-Castrillón et al \[[@CIT0012]\], and 49% reported by Meric et al \[[@CIT0014]\]. Pérez-Castrillón et al \[[@CIT0012]\] found an association between therapeutic failure and use of tetracyclines as initial treatment and with the ulceroglandular clinical form of disease. In the study by Meric et al \[[@CIT0014]\], all the patients had oropharyngeal tularemia, and a treatment delay of more than 2 weeks was associated with therapeutic failure. In our series, the ulceroglandular form represented 35% of the cases, there were no cases of oropharyngeal tularemia, and the average delay before appropriate treatment was 27 days.

The retrospective design of the study and the small number of patients are limitations of this study. In addition, we cannot rule out the possibility of selection bias if tetracyclines were prescribed because the disease severity was judged to be low. Further prospective controlled studies are needed to establish the most efficacious and convenient antibiotic therapy for tularemia, including severe cases. Information about subspecies or subpopulations in each treatment group may also provide valuable insight because different strains have different virulence and effect on outcomes \[[@CIT0004]\].

CONCLUSIONS {#s4}
===========

In conclusion, therapeutic failure was not observed after treatment of tularemia with tetracyclines along with prompt attention to drainage of abscessed lymph nodes. Duration of therapy of 21 days appears to be effective, particularly if aspiration or incision and drainage procedures are needed.
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